News Sentiment

OTLK sentiment intelligence

OUTLOOK THERAPEUTICS INC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.57 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Guidance

88/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

+8.3% over one week, +28.7% over four weeks, trend active, and below fair value.

Latest direct headline Positive

$Outlook Therapeutics (OTLK.US)$ looks like a cup and handle on the daily ans weekly chart. this should take off soon.

Market Reaction

Price moving ahead of tone

72/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Guidance 88/100 classification
One-week reaction 8.3% Price confirming higher
Trend fit Trend active 28.7% over four weeks
Fair value -68.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 34
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 10
Market source 9
Stock Titan 5
Moomoo 4
GlobeNewswire 4
simplywall.st 4
StocksToTrade 3
MT Newswires 3

Event Lens

What the news is about

Classified themes
Guidance 46
Earnings 14

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Market source Direct company coverage

Outlook Therapeutics (OTLK) Gets July 29 PDUFA Date for LYTENAVA

Outlook Therapeutics (OTLK) announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for ONS-5010/LYTENAVA, setting a PDUFA target action date of July 29, 2026. The FDA deemed the resubmission a Class 1 review, focusing on labeling as the fi

Tone
Positive 74/100
Event
Guidance
Published
14 Jul 2026 19:08
Source
Market source
StocksToTrade Direct company coverage

OTLK Jumps As FDA Accepts ONS-5010 Review And Nasdaq Risk Fades

Outlook Therapeutics Inc. (OTLK) saw its stock jump after the FDA accepted its resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava for wet AMD, setting a PDUFA target date of July 29, 2026. This potential approval would establish the first FDA-approved ophthalmi

Tone
Positive 75/100
Event
Guidance
Published
14 Jul 2026 18:12
Source
StocksToTrade
Moomoo Direct company coverage

Outlook Therapeutics Stock (OTLK) Opinions on Phase 3 Advancement

This article discusses Outlook Therapeutics' stock stability and analyzes the company's recent movement in shares after its ONS-5010 (Lytenava) received positive feedback from the FDA regarding its biologics license application. The article provides insights into the company's fi

Tone
Positive 75/100
Event
Guidance
Published
12 Jul 2026 20:41
Source
Moomoo
StocksToTrade Direct company coverage

OTLK Stock Holds Nasdaq Compliance As FDA Clock Starts

Outlook Therapeutics Inc. (OTLK) stock has seen a 14.73% increase due to positive news regarding its eye-treatment pipeline. The FDA accepted the resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava, setting a PDUFA target date of July 29, 2026. Additionally, OTL

Tone
Positive 66/100
Event
Guidance
Published
08 Jul 2026 16:33
Source
StocksToTrade
Moomoo Direct company coverage

Outlook Therapeutics | D: Filing D

This article provides a brief notification regarding Outlook Therapeutics, indicating a "Filing D" document has been reported. The content provided is minimal, only stating "Document."

Tone
Neutral 50/100
Event
Guidance
Published
08 Jul 2026 07:11
Source
Moomoo
TradingView Direct company coverage

Enterprise value to revenue forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK

This page from TradingView displays information regarding the enterprise value to revenue for Outlook Therapeutics, Inc. (NASDAQ: OTLK). It highlights the company's financial data within the health technology and pharmaceuticals sector. The content primarily focuses on the financ

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 12:09
Source
TradingView
Quiver Quantitative Direct company coverage

Outlook Therapeutics Stock (OTLK) Opinions on FDA Review for Lytenava

Outlook Therapeutics (OTLK) has regained Nasdaq listing compliance and is expanding its pipeline with multiple Phase 3 ophthalmology programs. The company's stock is under close watch ahead of the scheduled July 29 FDA review of its biologics license application for ONS-5010, whi

Tone
Positive 76/100
Event
Guidance
Published
01 Jul 2026 17:57
Source
Quiver Quantitative
Stocktwits Direct company coverage

These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why

Redwire (RDW), T1 Energy (TE), and Outlook Therapeutics (OTLK) shares experienced significant gains on Tuesday, driven by various factors. RDW benefited from optimism in the space sector following SpaceX's impending market debut, while TE soared due to strong institutional backin

Tone
Positive 86/100
Event
Guidance
Published
27 Jun 2026 18:10
Source
Stocktwits
Finviz Direct company coverage

OTLK - Outlook Therapeutics Inc Latest SEC Filings

This article provides the latest SEC filing information for Outlook Therapeutics Inc. (OTLK), along with a comprehensive overview of its financial performance, key statistical data, and market metrics. It includes details such as stock performance, analyst recommendations, and in

Tone
Neutral 50/100
Event
Guidance
Published
27 Jun 2026 16:11
Source
Finviz
Stock Titan Direct company coverage

Outlook Therapeutics (OTLK) restores Nasdaq minimum bid compliance, delisting threat closed

Outlook Therapeutics (OTLK) has successfully regained compliance with Nasdaq's minimum bid price requirement, effectively closing the delisting threat. The company's common stock traded at or above $1.00 per share for ten consecutive business days, satisfying Nasdaq Listing Rule

Tone
Positive 72/100
Event
Guidance
Published
26 Jun 2026 21:10
Source
Stock Titan
TradingView Direct company coverage

Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Outlook Therapeutics (OTLK) announced that it has regained compliance with Nasdaq's Listing Rule 5550(a)(2) regarding a minimum bid price. The company's closing bid price was at or above $1.00 for ten consecutive business days from June 11–25, 2026, leading Nasdaq to close the ma

Tone
Positive 70/100
Event
Guidance
Published
26 Jun 2026 21:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK

This article provides an "Enterprise value to EBITDA forward" metric for Outlook Therapeutics, Inc. (NASDAQ: OTLK). The content appears to be a financial data snippet from TradingView, indicating the value and changes for this specific financial ratio for the company. The article

Tone
Neutral 50/100
Event
Guidance
Published
26 Jun 2026 13:10
Source
TradingView
StocksToTrade Direct company coverage

OTLK Stock Climbs As FDA Fast-Tracks Lytenava Decision

Outlook Therapeutics Inc. (OTLK) stock climbed 8.7% after the FDA accepted its Biologics License Application (BLA) for ONS-5010/Lytenava as a Class 1 review, with a target decision date of July 29, 2026. The FDA's Office of New Drugs has found substantial evidence of effectivenes

Tone
Positive 76/100
Event
Guidance
Published
26 Jun 2026 12:33
Source
StocksToTrade
TradingView Direct company coverage

Outlook Therapeutics, Inc. Actuals & Estimates (NASDAQ:OTLK)

This article provides a comprehensive overview of Outlook Therapeutics, Inc. (OTLK) stock, including historical data, analyst forecasts, and financial performance. It covers various metrics such as current stock price, market capitalization, earnings, revenue, and future earnings

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 09:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Outlook Therapeutics, Inc. – MUN:41O

This article concerns the enterprise value to revenue dynamics for Outlook Therapeutics, Inc. (MUN:41O) on the Munich Stock Exchange. The content is primarily a placeholder from TradingView, offering no specific financial data or analysis beyond the initial statement of the topic

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 17:41
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK

This article provides the "Price to sales forward" financial metric for Outlook Therapeutics, Inc. (NASDAQ: OTLK). It highlights the company's financial data as presented on TradingView, a financial charting and analysis platform. The content is primarily a data point for investo

Tone
Neutral 50/100
Event
Guidance
Published
25 Jun 2026 15:41
Source
TradingView
TradingKey Direct company coverage

Outlook Therapeutics Inc (OTLK) Valuation: PE, PB & Fair Value Analysis

Outlook Therapeutics Inc (OTLK) currently holds a valuation score of 9.14, placing it 57th out of 388 companies in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.49, which is significantly lower than its recent high but higher than its recent low. The

Tone
Negative 40/100
Event
Guidance
Published
25 Jun 2026 10:40
Source
TradingKey
TradingView Direct company coverage

Price to book forward of Outlook Therapeutics, Inc. – MUN:41O

This article displays financial data for Outlook Therapeutics, Inc. (MUN:41O), specifically its "Price to book forward" metric. The content is presented within the TradingView platform interface, indicating a focus on financial analysis and market information for the pharmaceutic

Tone
Neutral 50/100
Event
Guidance
Published
25 Jun 2026 07:40
Source
TradingView
Moomoo Direct company coverage

Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News

This document, titled "Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News," is an empty placeholder. It indicates the subject matter relates to Outlook Therapeutics (OTLK) stock options, quotes, and news, but no content is provided.

Tone
Neutral 50/100
Event
Guidance
Published
22 Jun 2026 01:10
Source
Moomoo
Stocktwits Direct company coverage

OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision

Outlook Therapeutics (OTLK) saw its stock jump 28% after the FDA accepted its resubmitted biologics license application for LYTENAVA, setting a decision date of July 29, 2026. The drug, if approved, would be the first FDA-approved ophthalmic formulation of bevacizumab for wet age

Tone
Positive 74/100
Event
Guidance
Published
18 Jun 2026 09:40
Source
Stocktwits
TradingView Direct company coverage

OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review

Shares of Outlook Therapeutics (OTLK) surged 35.3% after the FDA accepted the resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava, its wet AMD treatment. The FDA classified it as a Class 1 resubmission with a decision date of July 29, 2026, marking the final sta

Tone
Positive 72/100
Event
Guidance
Published
17 Jun 2026 14:38
Source
TradingView
Stock Titan Direct company coverage

FDA sets July 29, 2026 PDUFA date for Outlook Therapeutics (OTLK) ONS-5010 BLA

Outlook Therapeutics announced that the FDA has acknowledged its resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA, a treatment for wet age-related macular degeneration. The resubmission was classified as a Class 1 review, leading to a 60-day review period and

Tone
Positive 66/100
Event
Guidance
Published
17 Jun 2026 11:40
Source
Stock Titan
The Pharma Letter Direct company coverage

FDA accepts resubmitted BLA from Outlook Therapeutics

Outlook Therapeutics saw its shares climb over 25% after the FDA accepted its resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava. This treatment is intended for age-related macular degeneration (AMD), and the FDA has designated it a Class 1 review with a target

Tone
Positive 71/100
Event
Guidance
Published
17 Jun 2026 09:38
Source
The Pharma Letter
GuruFocus Direct company coverage

Outlook Therapeutics (OTLK) Gains FDA Acknowledgment for BLA Resubmission

Outlook Therapeutics (OTLK) announced that the FDA has acknowledged the resubmission of its biologics license application (BLA) for ONS-5010 (Lytenava) to treat wet age-related macular degeneration, classifying it as a Class 1 review with a target action date of July 29, 2026. De

Tone
Positive 64/100
Event
Guidance
Published
16 Jun 2026 22:38
Source
GuruFocus